APOE was reported to attenuate unresolvable inflammation as a checkpoint by complex formation with activated C1q in the complement activation pathway and subsequently reducing C5 and the inflammatory burden in atherosclerosis and Alzheimer disease [32]. This evidence concerns the gene C5 and early-onset autosomal dominant Alzheimer disease.